Paper Details

  1. Home
  2. Paper Details

Updates on the Current Treatments for Diabetic Retinopathy and Possibility of Future Oral Therapy.

Author: KuriharaToshihide, LeeDeokho, NegishiKazuno, TomitaYohei, TsubotaKazuo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Diabetic retinopathy (DR) is a leading cause of vision loss worldwide, despite ongoing efforts to mitigate its impact. Early DR involves damage to vascular endothelial cells and pericytes, leading to hypoxia and the release of pro-angiogenic factors like VEGF. Current management focuses on blood glucose control, with laser therapies, anti-VEGF treatment, and vitrectomy for more advanced cases. While these treatments offer benefits, they also have limitations and side effects. Recent research has highlighted the link between DR, lipid metabolism, and inflammation. Peroxisome proliferator-activated receptor alpha (PPARα) activation, through oral fenofibrate or pemafibrate, shows promise as a therapeutic target in DR.
Paper Details　
Original Abstract of the Article :
Diabetic retinopathy (DR) is a complication of diabetes and one of the leading causes of vision loss worldwide. Despite extensive efforts to reduce visual impairment, the prevalence of DR is still increasing. The initial pathophysiology of DR includes damage to vascular endothelial cells and loss of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537579/

データ提供：米国国立医学図書館（NLM）

Diabetic Retinopathy: A Search for New Treatments

Diabetic retinopathy (DR) is a serious complication of diabetes that can lead to vision loss. This review explores the current landscape of DR treatment, a journey through a vast and complex medical desert. The authors discuss existing therapies like laser treatment, anti-VEGF therapy, and vitrectomy, while also exploring the potential of oral therapies like fenofibrate and pemafibrate, which could offer a new approach to managing DR.

A Promising New Frontier

The review highlights the potential of PPARα activation therapy for DR, a promising avenue for developing new treatments. It's like discovering a hidden oasis in the desert of DR research, offering hope for a more effective and less invasive way to manage this debilitating condition.

Managing Diabetic Retinopathy: A Comprehensive Approach

The authors emphasize the importance of comprehensive care, including tight blood glucose control, for managing DR. It's like ensuring that the camel is well-hydrated and properly equipped for the journey through the desert of diabetes. This review provides a valuable resource for understanding the current state of DR treatment and the potential for new therapies on the horizon.

Dr. Camel's Conclusion

This study offers a comprehensive overview of diabetic retinopathy treatment, shedding light on the challenges and opportunities in this complex medical field. It's like a guidebook for navigating the desert of DR, providing crucial information for both healthcare providers and patients. The authors' insights offer hope for better treatments and a more optimistic outlook on the future of DR management.

Date :
  1. Date Completed n.d.
  2. Date Revised 2021-10-26
Further Info :

Pubmed ID

34682788

DOI: Digital Object Identifier

PMC8537579

Related Literature

Article Analysis
・Side Effects of fenofibrate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.